Document and Entity Information - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2021

Mar. 10, 2022

Jun. 30, 2021

Cover [Abstract]

Document Type

10-K

Amendment Flag

false

Document Period End Date

Dec. 31, 2021

Document Fiscal Year Focus

2021

Document Fiscal Period Focus

FY

Entity Registrant Name

Ovid Therapeutics Inc.

Entity Central Index Key

0001636651

Current Fiscal Year End Date

--12-31

Entity Well-known Seasoned Issuer

No

Entity Current Reporting Status

Yes

Entity Voluntary Filers

No

Entity Filer Category

Non-accelerated Filer

Entity Interactive Data Current

Yes

Entity Ex Transition Period

true

ICFR Auditor Attestation Flag

false

Entity Common Stock, Shares Outstanding

70,373,162

Entity Public Float

$ 217.2

Entity Shell Company

false

Entity Small Business

true

Entity Emerging Growth Company

true

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

OVID

Security Exchange Name

NASDAQ

Entity File Number

001-38085

Entity Incorporation, State or Country Code

DE

Entity Tax Identification Number

46-5270895

Entity Address, Address Line One

1460 Broadway

Entity Address, Address Line Two

Suite 15021

Entity Address, City or Town

New York

Entity Address, State or Province

NY

Entity Address, Postal Zip Code

10036

City Area Code

646

Local Phone Number

661-7661

Documents Incorporated by Reference

Portions of the registrant’s definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Document Annual Report

true

Document Transition Report

false

Auditor Name

KPMG LLP

Auditor Location

New York, New York

Auditor Firm ID

185